1. Scrip
  2. >>Business

Advinus Ex-CEO's Bitter-Sweet Journey And Lessons Learnt

 
• By Anju Ghangurde

Life appears to have come full circle for Advinus Therapeutics' co-founder and former CEO and managing director, Dr Rashmi Barbhaiya, who recently moved back to the US from India. And it has been a bitter-sweet journey, replete with some peaks and troughs, although the man himself would rather term any lows as "lessons learned" that come with the territory.

"It is with mixed feelings I have returned to US after relentless pursuit of 14 years. I do want to keep the reins of my destiny in my hand," Barbhaiya, who began his industrial pharmaceutical career in 1980 with Bristol-Myers Squibb Co.in the US, told Scrip in an interview. He also lamented the limited understanding of investors in India of pharma R&D, but more on that later.

Barbhaiya, who was born in India, returned to the country from the US in 2002 to take charge as president of R&D at Ranbaxy Laboratories Ltd., which was then...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Summit’s Ivonescimab Shows Significance On PFS, But Not Overall Survival

 
• By Joseph Haas

In a study intended to show similar benefit in western patients, PD-1/VEGF-targeting ivonescimab met a progression-free survival endpoint, but missed on OS.

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By Kevin Grogan

One Phase III trial hits but a second study misses by a mile.

Astellas Gets CLDN.18.2-Targeted ADC From China’s Evopoint

 
• By Joseph Haas

Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.

All Over For iTeos But Applause For Plan To Return Cash Fast

 
• By Kevin Grogan

The company has moved quickly to wind down operations after its anti-TIGIT pact with GSK collapsed.

More from Scrip

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

 
• By Sushmita Panda

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.

Astellas Gets CLDN.18.2-Targeted ADC From China’s Evopoint

 
• By Joseph Haas

Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.

Merck & Co./Daiichi Pull Patritumab Deruxtecan BLA On Disappointing OS

 
• By Jessica Merrill

Patritumab deruxtecan is the lead antibody drug conjugate in a $22bn deal signed between the two partners, with the decision marking a disappointing setback